IGM Biosciences, Inc.
IGMSDelisted Aug 14, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001496323
IGM Biosciences, Inc. was delisted on Aug 14, 2025; its insiders filed their last Form 4 on Aug 18, 2025; 66 institutions reported holding it in 13F filings for Q2 2025, worth $17.9M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 66
- Q2 2025, −13 vs. previous quarter
- 13F value
- $17.9M
- Reported value at the end of Q2 2025
- Superinvestors holding
- 0
- At the end of Q2 2025
Superinvestors holding IGMS, Q2 2025
No superinvestor reported holding IGMS at the end of Q2 2025.
Latest insider trades
Open-market purchases and sales by IGM Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 25, 2025 (view filing) | Jul 23 | 2 days | Tahir MisbahCHIEF FINANCIAL OFFICER | SSale | −8.74K | $1.27 | −$11.1K | −4.9%170.1K after | |
| Jul 25, 2025 (view filing) | Jul 23 | 2 days | Harler Mary BethChief Executive Officer | SSale | −14.5K | $1.27 | −$18.4K | −4.3%323.7K after | |
| Jul 25, 2025 (view filing) | Jul 23 | 2 days | Decker Lisa LynnCHIEF BUSINESS OFFICER | SSale | −4.41K | $1.27 | −$5.60K | −6.1%68.2K after | |
| Jun 20, 2025 (view filing) | Jun 16 | 4 daysLate | Weber StevenPRINCIPAL ACCOUNTING OFFICER | SSale | −486 | $1.20 | −$583.2 | −1.8%26.5K after | |
| Jun 20, 2025 (view filing) | Jun 16 | 4 daysLate | Tahir MisbahCHIEF FINANCIAL OFFICER | SSale | −1.52K | $1.20 | −$1.83K | −0.8%178.8K after | |
| Jun 20, 2025 (view filing) | Jun 16 | 4 daysLate | Harler Mary BethChief Executive Officer | SSale | −1.52K | $1.20 | −$1.83K | −0.4%338.2K after | |
| Jun 20, 2025 (view filing) | Jun 16 | 4 daysLate | Decker Lisa LynnCHIEF BUSINESS OFFICER | SSale | −951 | $1.20 | −$1.14K | −1.3%72.6K after | |
| May 16, 2025 (view filing) | May 14 | 2 days | Weber StevenPRINCIPAL ACCOUNTING OFFICER | SSale | −1.86K | $1.12 | −$2.09K | −6.5%27.0K after | |
| Mar 18, 2025 (view filing) | Mar 14 | 4 days | Weber StevenPRINCIPAL ACCOUNTING OFFICER | SSale | −1.70K | $1.23 | −$2.09K | −5.6%28.9K after | |
| Mar 18, 2025 (view filing) | Mar 14 | 4 days | Tahir MisbahCHIEF FINANCIAL OFFICER | SSale | −7.33K | $1.23 | −$9.01K | −3.9%180.3K after |
Top 10 13F holders, Q2 2025
The largest institutional positions in IGM Biosciences, Inc. at the end of Q2 2025; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 4,096,210 | $4.59M | 0.04% | +9530.0% | Added |
| Siren, L.L.C. | 3,255,826 | $3.65M | 0.19% | 00.0% | Unchanged |
| Redmile Group, LLC | 2,952,131 | $3.31M | 0.35% | 00.0% | Unchanged |
| Sanofi | 1,438,975 | $1.61M | 0.92% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 855,286 | $957.9K | 0.00% | +61,900+7.8% | Added |
| Vanguard Group Inc | 767,154 | $859.2K | 0.00% | −108,415−12.4% | Reduced |
| BlackRock, Inc. | 385,474 | $431.7K | 0.00% | −645,050−62.6% | Reduced |
| Millennium Management LLC | 275,112 | $308.1K | 0.00% | +275,112 | New |
| Geode Capital Management, LLC | 213,273 | $239.0K | 0.00% | −212,387−49.9% | Reduced |
| Jane Street Group, LLC | 180,985 | $202.7K | 0.00% | +180,985 | New |
Holders of 5% or more of IGMS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of IGM Biosciences, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Price T Rowe Associates Inc | 13G/A | 10.50%3.57M shares | +10.30 ppfrom 0.20% | Feb 7, 20252 filings | Feb 14, 2025 | SEC |